SCHEMBL5149083

SCHEMBL5149083

CC(C)n1nc(-c2nc(/C=C/c3ccccc3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.43
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
GLA P06280 2/20 0.37
PTGS1 P23219 2/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MAPK1 P28482 2/20 0.34
TP53 P04637 2/20 0.34
GRM4 Q14833 3/20 0.33
POLB P06746 2/20 0.33
NPC1 O15118 2/20 0.33
GAA P10253 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
KDM5B Q9UGL1 1/20 0.33
ABL1 P00519 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149089 1.00 RET (0.43) RETKDM4EALDH1A1HPGDGLA
SCHEMBL5147958 0.84 ADORA2A (0.39) RETKDM4EALDH1A1HPGDGLA
SCHEMBL5149110 0.82 PDE1A (0.41) RETKDM4EALDH1A1HPGDRAB9A
SCHEMBL5149084 0.82 ALDH1A1 (0.40) KDM4EALDH1A1HPGDGLARAB9A
SCHEMBL5149088 0.82 ALDH1A1 (0.40) KDM4EALDH1A1HPGDGLARAB9A
SCHEMBL5149012 0.81 TP53 (0.35) RETKDM4ESMN1; SMN2TP53POLB
SCHEMBL5148960 0.81 POLB (0.39) RETKDM4EALDH1A1HPGDGLA
SCHEMBL5150753 0.81 ADORA2A (0.38) RETKDM4ETP53POLBABL1
SCHEMBL5149057 0.81 TP53 (0.36) RETKDM4ETP53POLBABL1
SCHEMBL5149001 0.79 MEN1 (0.36) RETKDM4ERAB9ATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 RET 2434/4885KDM4E 3683/4885ALDH1A1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.